Revenue Recognition (Tables)

3 Months Ended

Mar. 31, 2021

Disaggregation of Revenue [Abstract]

Disaggregation of Revenue [Table Text Block]

The following table summarizes the disaggregation of revenue by nature:

	Three Months Ended March 31,
Dollars in Millions	2021		2020
Net product sales	$	10,798	$	10,541
Alliance revenues	142		105
Other revenues	133		135
Total Revenues	$	11,073	$	10,781

Revenue Recognition Gross-To-Net Adjustments [Table Text Block]

The following table summarizes GTN adjustments:

	Three Months Ended March 31,
Dollars in Millions	2021		2020
Gross product sales	$	15,559	$	14,686
GTN adjustments(a)
Charge-backs and cash discounts	(1,586)		(1,340)
Medicaid and Medicare rebates	(1,718)		(1,498)
Other rebates, returns, discounts and adjustments	(1,457)		(1,307)
Total GTN adjustments	(4,761)		(4,145)
Net product sales	$	10,798	$	10,541

(a)    Includes adjustments for provisions for product sales made in prior periods resulting from changes in estimates of $217 million and $72 million for the three months ended March 31, 2021 and 2020, respectively.

Revenue from External Customers by Products and Services [Table Text Block]

The following table summarizes the disaggregation of revenue by product and region:

	Three Months Ended March 31,
Dollars in Millions	2021		2020
Prioritized Brands
Revlimid	$	2,944	$	2,915
Eliquis	2,886		2,641
Opdivo	1,720		1,766
Orencia	758		714
Pomalyst/Imnovid	773		713
Sprycel	470		521
Yervoy	456		396
Abraxane	314		300
Empliciti	85		97
Reblozyl	112		8
Inrebic	16		12
Onureg	15		—
Zeposia	18		—
Established Brands
Vidaza	54		158
Baraclude	113		122
Other Brands	339		418
Total Revenues	$	11,073	$	10,781
United States	$	7,010	$	6,766
Europe	2,553		2,567
Rest of the World	1,346		1,335
Other(a)	164		113
Total Revenues	$	11,073	$	10,781

(a)    Other revenues include royalties and alliance-related revenues for products not sold by BMS’s regional commercial organizations.